drugset / Trial / NCT01284322
Fresolimumab In Systemic Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
Timeline
- Start
- 2011-01
- Primary completion
- 2013-06
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fresolimumab | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | Fresolimumab | Protein / enzyme biologic | 5 mg/kg | Intravenous |